The UK and US have forged a major trade agreement that will preserve no tariffs on UK pharmaceutical exports going into the American market.
The Terms of the Deal
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the public health system. This pledge ensures that tariffs on these vital goods will be held at zero for a duration of 36 months.
This agreement is in response to recent statements to hike import taxes on branded pharmaceutical products, with figures discussed up to 100%.
"This agreement between the Britain strengthens the global environment for new treatments and establishes much-needed balance to U.S.–U.K. drug exports," a release declared.
Commercial Impact
Pharmaceuticals represent one of the Britain's most significant goods shipped to the United States, which is clearly the largest destination for large UK drugmakers.
Export figures reveal that in the year to the end of the third quarter, the UK shipped drugs worth £11.1bn to the US. This value represented 17.4% of all goods exports in that timeframe.
"This deal secures jobs, stimulates funding and sets the stage for the UK to become a global hub for biotech and pharma," a minister remarked.
Detailed British Pledges
The agreement includes several notable pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to double overall NHS spending on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to control costs will be capped at fifteen percent. Previously, repayments were more than 20%.
Industry Background
The deal follows a protracted row between the sector and the British authorities over spending levels and approval rates.
The disagreement were intensified by assertions that US customers were paying several times more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its expenditure on drugs had declined as a share of its resources over the past decade.
